Newsroom

Newsroom

Featured News

Date Title and Summary
Toggle Summary Genomic Health Marks More than 1 Million Patients Worldwide Who Have Benefited from Oncotype DX Testing in Personalizing Cancer Treatment Decisions to Improve Outcomes
Pioneering Precision Medicine While Saving Healthcare Costs REDWOOD CITY, Calif. , Jan. 7, 2019 /PRNewswire/ --  Genomic Health , Inc.  (NASDAQ: GHDX) today announced that, in collaboration with physicians around the world, it has delivered more than 1 million Oncotype DX ® tests to cancer patients
Toggle Summary New NCCN Breast Cancer Guidelines Elevate Oncotype DX Breast Recurrence Score® as the Only Preferred Multi-gene Test to Predict Chemotherapy Treatment
Updated NCCN Guidelines Underscore the Unique Advantage of the Oncotype DX® Test in Predicting Chemotherapy Benefit REDWOOD CITY, Calif. , Oct. 9, 2018 /PRNewswire/ -- Genomic Health, Inc.  (NASDAQ: GHDX) today announced that its Oncotype DX Breast Recurrence Score ® test has been categorized as
Toggle Summary German Health Technology Assessment Body (IQWiG) Concludes Only Oncotype DX® has Sufficient Evidence to Guide Breast Cancer Adjuvant Chemotherapy Decisions Based on Landmark TAILORx Study Results
Updated Assessment of Breast Cancer Gene Expression Profiling Tests for Clinical Use in Germany Final German Federal Joint Committee (G-BA) Reimbursement Decision Expected by End of 2018 REDWOOD CITY, Calif. , Sept. 7, 2018 /PRNewswire/ --  Genomic Health, Inc.  (NASDAQ: GHDX) today announced the
Toggle Summary Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Demonstrate the Oncotype DX Breast Recurrence Score® Test Definitively Identifies the 70% of Women with Early-stage Breast Cancer Who Receive No Benefit from Chemotherapy, and the 30% of Women for Whom Chemotherapy Benefit Can be Life-saving
Independently Led by ECOG-ACRIN Research Group, TAILORx Prospective, Randomized Phase III Clinical Trial Results to be Presented Today in the Plenary Session at ASCO Annual Meeting TAILORx-defined Cutoff for Definitively Determining Chemotherapy Benefit with Oncotype DX® Usher in a New Era in the

Latest Press Releases

Date Title and Summary
Toggle Summary Genomic Health to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on Wednesday, February 20, 2019
REDWOOD CITY, Calif. , Feb. 13, 2019 /PRNewswire/ --  Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Wednesday, February 20 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end 2018 financial results.
Toggle Summary Oncotype DX® Genomic Prostate Score® Established as First Genomic Test with Prospective Validation for Predicting Adverse Pathology in Newly Diagnosed Patients
Results, Published in Urology, Represent First Prospective Validation of Critical Endpoint to Identify Patients for Active Surveillance REDWOOD CITY, Calif. , Feb. 5, 2019 /PRNewswire/ --  Genomic Health, Inc . (Nasdaq: GHDX) today announced the publication of results from a multi-center,
Toggle Summary Genomic Health Marks More than 1 Million Patients Worldwide Who Have Benefited from Oncotype DX Testing in Personalizing Cancer Treatment Decisions to Improve Outcomes
Pioneering Precision Medicine While Saving Healthcare Costs REDWOOD CITY, Calif. , Jan. 7, 2019 /PRNewswire/ --  Genomic Health , Inc.  (NASDAQ: GHDX) today announced that, in collaboration with physicians around the world, it has delivered more than 1 million Oncotype DX ® tests to cancer patients
Toggle Summary NICE Expands Recommendation for the Oncotype DX Breast Recurrence Score® Test to More Patients with Early-Stage Breast Cancer Within the United Kingdom
- Only test recommended based on its ability to predict chemotherapy benefit - Recommendation expanded to include patients with micrometastatic disease REDWOOD CITY, Calif. , Dec. 19, 2018 /PRNewswire/ --  Genomic Health, Inc. (NASDAQ: GHDX) today announced that the National Institute for Health

Patient & Physician Stories

 

 
 

Your Prostate, Your Decision: A Patient's Perspective

1559 views 09/24/2014

Watch the Video

Do You Know Your Oncotype DX Score?

174 views 09/29/2015

Watch the Video

Oncotype DX DCIS Breast Cancer Score: Amy's Story

8370 views 07/17/2013

Watch the Video

An Oncotype DX Breast Cancer Treatment Story from Mexico (MX)

644 views 11/13/2012

Watch the Video

Dr. Peter Carroll on the Validation of the Oncotype DX Prostate Cancer Test

299 views 12/08/2015

Watch the Video

Dr. Joseph Sparano on the Necessity of Oncotype DX Genomic Testing in Breast Cancer

164 views 12/08/2015

Watch the Video

 

Social Media

Learn About the Oncotype DX Prostate Cancer Test

13600 views 05/04/2013

Watch the Video

Genomic Health and Oncotype IQ – Delivering Precision Medicine

67 views 09/06/2018

Watch the Video

Oncotype DX AR-V7 Nucleus Detect test

528 views 08/10/2018

Watch the Video